Nanomedicine lecture series: Nanotechnology in neurology and neurosciences, Thursday, 9 November 2017

Written by UMIP on . Posted in News

Our second lecture in the nanomedicine lecture series, to be held on Thursday, 9 November 2017 in UMIC’s Core Technology Facility Dalton Room, will focus on nanotechnology in neurology and neurosciences, exploring the bridge between technology and neuroscience.

Keynote speakers:

The following pre-eminent global leaders in biomedical science will be keynote speakers at this event:

  • Professor Dame Nancy Rothwell, President and Vice-Chancellor of The University of Manchester
  • Professor Ed Boyden, Associate Professor, Media Lab and McGovern Institute, Departments of Biological Engineering and Brain and Cognitive Sciences Co-Director, MIT Centre for Neurobiological Engineering
  • Professor John Hardy, University College London

Registration:

Please register via Eventbrite: https://www.eventbrite.co.uk/e/nanomednetwork-lecture-series-2-nanotechnology-in-neurologyneurosciences-tickets-34568005836

Please contact Sarah Barton (sarah.barton@manchester.ac.uk) in the FBMH Strategic Funding Team with any queries.

About the NanoMed Network:

The University of Manchester NanoMed Network is a cross-faculty interdisciplinary network that aims to facilitate the exploitation of novel nanomaterials and nanotechnologies, such as graphene and other 2D materials, in order to provide solutions for unmet clinical challenges.

NanoMed Network website.

2D Materials IP Portfolio Manager

Written by admin on . Posted in Vacancies

  • Managing the University’s IP portfolio relating to 2D materials (including graphene)
  • Working collaboratively with University researchers
  • Selecting new IP development projects and securing funding
  • Securing licences and spinning out companies
  • Project team leadership and management
  • Manchester
  • £60,000 plus bonus scheme and benefits package

The University of Manchester I3 Ltd (UMI3) is a wholly-owned company of the University of Manchester and its agent for Intellectual Property (IP) management and commercialisation. UMIP is the division of UMI3 whose role is to commercialise intellectual property (IP), know-how and technology developed at the University. Since its inception in 2004, UMI3 has created 40 spin-out companies, managed over £300m of third party investment into the University’s spin-outs and brokered over 4,800 licences and assignments. UMI3 is widely recognised as being amongst the leading university technology transfer organisations in the UK.

Due to the University’s research excellence in 2D Materials, including graphene, the University has generated a significant 2D IP portfolio. This new senior role has been created within UMIP to manage that portfolio strategically, in the context of broad industrial partnerships, as a platform to secure commercial licences, create spin out companies and build reputational and commercial value. This individual will be responsible for leading a project team which identifies new 2D IP from relevant University research, leverages development funding, secures licences and creates spin out companies, supported by colleagues within UMIP and related cognate groups of the University. The individual will be a positive ambassador for UMIP within the University and externally, and will ultimately co-locate with that research activity, where they will proactively champion the IP agenda. The Team Leader will manage the UMIP 2D Materials IP Project Team, report to UMIP’s Director of Operations, be a member of UMIPs Divisional Management Team (DMT) and attend the 2D Materials IP Project Board.

Candidates for this exciting role will have a strong and broad-based understanding of science and may have some familiarity with 2D Materials. They will be adept at placing new scientific concepts into commercial context and experienced in assessing, managing, developing and commercialising IP. They will be educated to at least degree level in a scientific subject and in addition will preferably hold a PhD and/or business qualification (or equivalents). A proven ability to build strong working relationships with academics, industry colleagues and partners will be a key criterion for success in this role. We are looking for an action-orientated candidate who will lead this activity to the next level, mobilise the 2D IP Portfolio and achieve commercial success.

For such an individual, we offer a generous salary, bonus scheme and benefits package and the opportunity to join a dynamic, forward-thinking technology transfer company associated with one of the UK’s top research universities.

Written applications, enclosing CV, to Mary Williams. Email to (mary.williams@umip.com) or by post FAO Mary Williams, UMIP, The Incubator Building, 48 Grafton St, Manchester M13 9XX.

Candidates selected for interview will be notified by email. Unsuccessful applicants will not be notified; should you not have received a response two weeks after the closing date for applications, we regret that your application will not have been successful.

Closing Date: 7th July 2017

Click here for job description

How to secure impact from your research by protecting and exploiting intellectual property

Written by UMIP on . Posted in News

Monday 26th June 2017

12.00pm -1.30pm (inc. buffet lunch)

Joule Suite, CTF Building, Grafton Street

Come along and hear about the different ways in which the intellectual property arising from your research can be protected, and the routes by which this can enable huge commercial, social or health impacts to be secured. Engage with an expert panel of lawyers, patent agents and business development executives to find out:

  • How and why patents are used as a tool to create economic value from research.
  • After filing a patent application what comes next?
  • How to decide whether impact should be secured through a new company, or under license to existing companies.
  • How to work with the confidentiality requirements
  • of the patenting system to ensure your publication record is not affected.
  • Other mechanisms to protect your intellectual property, beyond the patenting system.
  • How a REF impact case can be built from exploiting intellectual property

Please register here

The Panel consists of:

Jonathan Moakes

Gateley Plc

Judith Gracey

Knowledge

Exchange and

Impact Coordinator (UoM)

Richard Young

BVCA

Andrew Wells

HGF

Ean Davies

Appleyard Lees

The Bioscience Translation Challenge

Written by UMIP on . Posted in News

You are invited to attend a half-day event called “The Bioscience Translation Challenge” that will take the form of a panel discussion on the challenges of commercialising science.

When: 22nd June, 2017 (10:00-12:00 followed by lunch and networking)

Where: Kendrew Lecture Theatre, EBI. Wellcome Genome Campus Conference Centre

Host: BioData Innovation Centre

Panel members include:
Dr Uday Phadke, Cartezia, Cambridge, UK
Dr Shai Vyakarnam, Bettany Centre, Cranfield University, UK
Dr Adrian Ibrahim, Wellcome Sanger Institute, Hinxton, UK
Dr Martino Picardo, Stevenage Bioscience Catalyst, UK
Dr Robert Tansley, Cambridge Innovation Capital, Cambridge, UK

Why attend? Network with bioscience start-ups, high growth firms, R&D organisations, service providers and investors active in this field and gain a deeper understanding of how to translate research and development into products and services of commercial and societal value.

Spaces are limited, so you if you are interested in attending, please REGISTER ONLINE NOW to avoid disappointment.

University of Manchester skin specialist spin-out AIMs high with £4.5M float

Written by UMIP on . Posted in News

skinbio logo

 

 

Skin health company, SkinBioTherapeutics, a University of Manchester spin-out, will focus on developing and commercialising its SkinBiotix® technology platform after making a stunning debut on the London stock market.

The life sciences company raised £4.5 million on AIM last week. The funds raised will enable it to drive forward its development portfolio of three programmes – in skin care (sensitive skin), anti-infection and eczema. Due to size of the target markets (multi-billion $), the Company will seek to license out its programmes at an early stage to bigger companies with the specialism and resource to commercialise them.

Spun out of The University of Manchester by its Innovation Company UMI3 Ltd in April 2016, SkinBioTherapeutics was formed around the scientific discoveries coming from the work performed by University researchers Dr. Catherine O’Neill and Professor Andrew McBain.

SkinBioTherapeutics uses extracts of probiotic bacteria that in skin models have been shown to increase the skin’s barrier integrity to retain moisture better, protect the skin from infection and to increase the rate of skin healing in response to injury.

Dr. Catherine O'Neill - HeadshotChief executive Dr Catherine O’Neill, said: “Listing on AIM is a significant milestone for SkinBioTherapeutics and will give us the visibility we need amongst the established global players we are looking to partner with.

“The funds raised will enable us to accelerate the clinical development of our main therapeutic candidates and to progress the SkinBiotix® technology platform.

“This is an exciting time to be in the microbiome space, especially with regards to skin health. We have an experienced team and Board, plus the financial and shareholder support to maximise this opportunity.”

Dr Rich Ferrie of UMI3 said: “I am delighted that SkinBioTherapeutics has been admitted to AIM. Our team has worked closely with Cath and Andrew to prime the intellectual property arising from their exciting research for commercialisation.

“I am sure the SkinBiotix® platform will give rise to many important products in the skin health area and I look forward to the future success of SkinBioTherapeutics plc.”

Find out more about SkinBioTherapeutics at www.skinbiotherapeutics.com

The images show human skin which has been stained with a green dye to visualise a protein, critical to skin function as a barrier between the body and the environment. The level of this protein increases dramatically following treatment with a particular bacterium (compare ‘treated’ with ‘untreated’)
untreated

Untreated

treated

Treated

UMIP - REPUTATION AND VALUE THROUGH INTELLECTUAL PROPERTY®

Privacy Policy / Terms and Conditions / © Copyright 2015 The University of Manchester Intellectual Property / Created by HTP Digital Marketing Agency

The University of Manchester Intellectual Property ("UMIP") acts solely as agent for the University in relation to any matter relating to intellectual property ("IP") and know how created at the University. This is whether such IP is created by employees, students or others. UMIP does not represent anyone else in such matters. If anyone else requires advice in relation to such IP then they must take their own independent legal advice.